Safe Implementation of Thrombolysis in Stroke International Stroke Thrombolysis Register "SITS-ISTR"

Active, not recruiting

Phase N/A Results

Results

In the 3—4·5-h cohort, treatment was started at a median of 55 min later after symptom onset (195 min [IQR 187—210] vs 140 min [115—165], p<0·0001), median age was 3 years younger (65 years [55—73] vs 68 years [58—74], p<0·0001), and stroke severity was lower (NIHSS score 11 [7—16] vs 12 [8—17], p<0·0001) than in the 3-h cohort. We recorded no significant differences between the 3—4·5-h cohort and the within 3-h cohort for any outcome measure—rate of symptomatic intracerebral haemorrhage: 2·2% (14 of 649) versus 1·6% (183 of 11 681) (odds ratio [OR] 1·18 [95% CI 0·89—1·55], p=0·24; adjusted OR 1·32 [1·00—1·75], p=0·052); mortality: 12·7% (70 of 551) versus 12·2% (1263 of 10 368) (OR 1·02 [0·90—1·17]; p=0·72; adjusted OR 1·15 [1·00—1·33]; p=0·053); and independence: 58·0% (314 of 541) versus 56·3% (5756 of 10231) (OR 1·04 [0·95—1·13], p=0·42; adjusted OR 0·93 [0·84—1·03], p=0·18).